Clinical TrialMay 22, 2026, 08:11 AM
BioNTech to Present Late-Stage Oncology Pipeline Data at ASCO 2026
AI Summary
BioNTech SE announced it will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include encouraging anti-tumor activity for pumitamig in first-line non-small cell lung cancer and durable anti-tumor activity with clinically meaningful overall survival for gotistobart in platinum-resistant ovarian cancer. The company's diversified oncology pipeline features over 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials and novel-novel combination approaches.
Key Highlights
- Pumitamig data from Phase 2/3 ROSETTA Lung-02 trial showed encouraging anti-tumor activity in first-line non-small cell lung cancer (NSCLC).
- Gotistobart Phase 2 PRESERVE-004 trial data showed durable anti-tumor activity and clinically meaningful overall survival in platinum-resistant ovarian cancer (PROC).
- BioNTech's late-stage oncology pipeline includes over 25 Phase 2 and Phase 3 clinical trials.
- The pipeline features 13 ongoing pivotal trials and novel-novel combination trials, including antibody-drug conjugates (ADCs).
- New data for pumitamig and gotistobart will be highlighted in two oral presentations at ASCO 2026.
- Four trial-in-progress poster presentations will showcase ongoing pivotal and novel-novel combination trials.
Price Impact
More from BNTX